treated HMVECs from the RA synovial fibroblast coculture system had decreased endothelial cell tube formation compared with control siRNA-treated HMVECs.
Conclusion. These data show that ADAM-10 is overexpressed in RA and suggest that ADAM-10 may play a role in RA angiogenesis. ADAM-10 may be a potential therapeutic target in inflammatory angiogenic diseases such as RA.
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction (1) . RA synovium contains high levels of inflammatory cytokines and abundant inflammatory cells, including infiltrating lymphocytes and monocytes (2) . Synovial tissue (ST) macrophages represent one of the inflammatory cell types involved in RA pathogenesis. ST macrophages produce several cytokines, such as tumor necrosis factor ␣ (TNF␣) and interleukin-1␤ (IL-1␤) (3, 4) . Extensive studies have identified TNF␣ as a key inflammatory mediator in RA, and treatment of RA has been revolutionized by the introduction of therapies blocking this cytokine. However, despite suppression of this cytokine with anti-TNF␣ therapy, not all patients with RA experience improvement with such treatment (5) .
Angiogenesis is important in a variety of vasculoproliferative states, such as wound repair and RA (6, 7) . Many inflammatory mediators are also angiogenic mediators in RA ST and RA synovial fluid, including IL-8/CXCL8 (7) . The process of angiogenesis is often of pivotal importance in disease progression and thus is an interesting and promising therapeutic target (8) .
ADAMs are a family of proteases that are responsible for the liberation of a variety of cell surfaceexpressed proteins. ADAMs have been implicated in several inflammatory and degenerative pathologic conditions (9) . ADAM-10 is involved in the shedding of many substrates that play roles in cancer progression, myristate acetate (PMA; Sigma-Aldrich), lipopolysaccharide (LPS) derived from Escherichia coli O111 (Sigma-Aldrich), recombinant human interleukin-17 (rhIL-17), rhIL-1␤, or human rhTNF␣ (all from R&D Systems). The concentrations of the mediators that were used have been previously described (22) . Cell lysis and Western blotting were also performed as previously described (21) . Membranes were probed with rabbit anti-human ADAM-10 antibody (Abcam). Densitometric analysis of the bands was performed using Un-Scan-It software, version 5.1 (Silk Scientific).
RNA extraction and quantitative reverse transcriptionpolymerase chain reaction (RT-PCR). RNA extraction and quantitative RT-PCR were performed as previously described (23) . The ADAM-10 and actin primer pairs were purchased from Invitrogen. All samples were run in duplicate, and Eppendorf software was used to analyze the read-out data.
RNA silencing. HMVECs were seeded in 6-well plates at a density of 1 ϫ 10 5 cells/well. The cells were maintained in growth factor complete endothelial cell basal medium, at which time they were 60-70% confluent. Small interfering RNA (siRNA; 100 nM) against ADAM-10 or nonsilencing siRNA and TransIT-TKO (Mirus) in 250 l serum-free endothelial basal medium were mixed gently at room temperature for 15 minutes to allow complexes to form. Thereafter, 1,250 l of complete medium without antibiotics was added, and the resultant solution was mixed and overlaid on the cells. Cells were incubated with the siRNA and TransIT-TKO for 24 hours at 37°C. Control and ADAM-10 siRNA were purchased from Invitrogen. The target sequences of siRNA specific for ADAM-10 or control were as follows: for ADAM-10-1, 5Ј-GAGGAAAUACCAGAUGACUGGUGUA-3Ј; for ADAM-10-2, 5Ј-UACACCAGUCAUCUGGUAUUUCCUC-3Ј; for control, 5Ј-GACCGAAUGGGUUCUAAGAAACACA-3Ј. The siRNA sequences for both ADAM-10-1 and ADAM-10-2 are provided in the same master mixture (Invitrogen). To investigate the transfection efficiency of cells, fluoresceinconjugated nonsilencing siRNA (Santa Cruz Biotechnology) was transfected into cells with TransIT-TKO. The percent knockdown of ADAM-10 expression was determined using quantitative RT-PCR and Western blotting. In order to investigate whether knockdown was specific, we used quantitative RT-PCR to assess the expression of ADAM-8, ADAM-9, and ADAM-12.
Enzyme-linked immunosorbent assay (ELISA). Ninety-six-well plates were coated with synovial fluid from patients with RA, synovial fluid from patients with PsA, or recombinant ADAM-10 (R&D Systems), which was used as a standard. Goat anti-human ADAM-10 antibody (R&D Systems) was added as a primary antibody. The plates were then washed, and biotinylated horse anti-goat antibody (Vector) was added, followed by streptavidin-horseradish peroxidase (streptavidin-HRP; BD Biosciences). The plates were developed using tetramethylbenzidine substrate (TMB; SigmaAldrich) and were read on a microplate reader.
Ninety-six-well plates were coated with rabbit antihuman CXCL16 antibody (PeproTech) or mouse anti-human CX3CL1 antibody (R&D Systems). ADAM-10 siRNA-or control siRNA-treated HMVEC-conditioned medium, recombinant CXCL16 (PeproTech), or CX3CL1 (R&D Systems), used as a standard, was added. Biotinylated rabbit anti-human CXCL16 antibody or mouse anti-human CX3CL1 antibody was used to detect CXCL16, using a streptavidin-peroxidase method (BD Biosciences) with TMB. The concentration in each sample was measured at 450 nm.
A direct ELISA was also developed using recombinant soluble junctional adhesion molecule A (sJAM-A; R&D Systems) or sJAM-C (R&D Systems) as a standard, and 96-well plates were coated with standard or samples overnight at 4°C. The conditioned medium was added directly to the plate. Goat anti-human JAM-A antibody (R&D Systems) or goat antihuman JAM-C antibody (R&D Systems) was added as a primary antibody. The plates were then washed, and biotinylated horse anti-goat antibody (Vector) was added, followed by streptavidin-HRP (BD Biosciences). The plates were developed using TMB and were read on a microplate reader.
In vitro HMVEC chemotaxis assay. Chemotaxis assays were performed using a 48-well modified Boyden chamber system, as previously described (24, 25) . In order to confirm the role of ADAM-10, we performed HMVEC chemotaxis assays using recombinant ADAM-10 (100 nM; R&D Systems), control siRNA-transfected HMVEC-conditioned medium, and ADAM-10 siRNA-transfected HMVEC conditioned medium.
HMVECs were transfected with control siRNA or ADAM-10 siRNA, using TransIT-TKO. HMVECs treated with control siRNA (100 nM) or ADAM-10 siRNA (100 nM) were placed in the bottom wells of the chambers, and diluted RA synovial fluid (1:10 in phosphate buffered saline [PBS] ) was added to the top wells of the chambers. In addition, basic fibroblast growth factor (bFGF; 60 nM) or vascular endothelial growth factor (VEGF; 10 nM) (R&D Systems) was used as a positive control. Readings represent the number of cells migrating through the membrane (the sum of 3 high-power fields/well, averaged for each quadruplicate well).
In vitro Matrigel tube formation assay. Matrigel tube formation assays using growth factor-reduced Matrigel (BD Biosciences) were performed (26, 27) . HMVECs were transfected with control or ADAM-10 siRNA, using TransIT-TKO. Basic FGF (10 nM) or VEGF (1 nM) was used as a positive control, and PBS was used as a negative control. The treated HMVECs (1.8 ϫ 10 4 cells/400 l) were plated on Matrigel in the presence of bFGF, VEGF, or PBS for 6 hours at 37°C. Photographs (100ϫ magnification) were obtained, and an observer counted the tubes in a blinded manner. Tubes were defined as elongated connecting branches between 2 identifiable HMVECs.
Endothelial cell tube formation assay using cocultured HMVECs and RA synovial fibroblasts. In order to confirm the influence of ADAM-10 on tube formation by HMVECs, we cocultured HMVECs and RA synovial fibroblasts using a Transwell system (28) . HMVECs were first transfected, as described above, with either control siRNA or ADAM-10 siRNA and were plated in the bottom of the Transwell system. RA synovial fibroblasts were concurrently grown on the top inserts. HMVECs and RA synovial fibroblasts were cocultured with serum-free medium for 24 hours. HMVECs were collected from the coculture plates and subsequently plated on Matrigel in serum-free medium for 6 hours at 37°C. Tubes formed by HMVECs were counted by an observer in a blinded manner.
Conditioned medium from the coculture system was then used in an in vitro Matrigel assay in which the medium was added to HMVECs to determine whether tube formation could be altered. To do this, HMVECs from the coculture system were plated on Matrigel with the cocultured conditioned medium for 6 hours at 37°C, and an observer counted the number of tubes in a blinded manner.
Statistical analysis. Data were analyzed using Student's t-test, assuming equal variances. Data are reported as the mean Ϯ SEM. P values less than 0.05 were considered significant.
RESULTS

Expression of ADAM-10 on endothelial cells and ST lining cells.
We hypothesized that ADAM-10 is overexpressed in RA ST and plays a role in angiogenesis in RA. To test this hypothesis, we first determined whether endothelial cells and RA synovial fibroblasts could be induced to express ADAMs. ADAM expression was determined in RA, OA, normal, and PsA ST samples and in the joints of mice with K/BxN serumtransfer arthritis, using immunohistologic staining. Both synovial inflammation and vascularity were significantly increased in RA ST samples compared with OA and normal ST samples (P Ͻ 0.05; results not shown).
Figures 1A-D show representative photomicrographs of sections stained for ADAM-10 or control IgG antibody. Endothelial cells within RA ST expressed high levels of ADAM-10 (mean Ϯ SEM 46 Ϯ 7%), while endothelial cells within OA ST and normal ST expressed significantly less ADAM-10 (9 Ϯ 3% and 1 Ϯ 1%, respectively) ( Figure 1I ). Expression of ADAM-10 on endothelial cells within PsA ST (n ϭ 1) was 2%. However, there was no correlation between ADAM-10 expression and vascularity. ADAM-10 was highly expressed on lining cells in RA ST (72 Ϯ 6%), while lining cells within OA ST and normal ST expressed significantly less ADAM-10 (47 Ϯ 11% and 9 Ϯ 3%, respectively) ( Figure 1J ). Expression of ADAM-10 on lining cells within PsA ST was 4%. When experiments examining ADAM-8, ADAM-9, and ADAM-12 expression were performed, no differences were observed between RA ST and OA ST for any cell type (results not shown).
Figures 1E-H show the joints of mice with K/BxN serum-induced arthritis and nonarthritic controls immunostained with ADAM-10 or control IgG antibody. ADAM-10 was overexpressed on lining cells in mice with K/BxN serum-induced arthritis (day 12) compared with mice without arthritis (day 0) (mean Ϯ SEM 64 Ϯ 6% versus 21 Ϯ 11%) ( Figure 1K ). However, ADAM-10 expression on endothelial cells in the joints was not different between the mice with K/BxN serum-induced arthritis and the normal control group (0.5 Ϯ 0.2% versus 0.1 Ϯ 0.1%).
Elevated ADAM-10 concentration in RA synovial fluid compared with PsA synovial fluid. In order to examine ADAM-10 secretion, we performed an 100 ISOZAKI ET AL ADAM-10 ELISA with synovial fluid. The ADAM-10 concentration in RA synovial fluid (n ϭ 17) was significantly elevated compared with that in PsA synovial fluid (n ϭ 6) (mean Ϯ SEM 50 Ϯ 3 ng/ml and 37 Ϯ 3 ng/ml, respectively) ( Figure 1L ). Expression of ADAM-10 on HMVECs and RA synovial fibroblasts. To determine whether ADAM-10 was expressed by endothelial cells and RA synovial cells and whether its expression was regulated by proinflammatory cytokines or proangiogenic mediators, Western blotting and quantitative PCR were performed. ADAM-10 expression at the protein level was significantly elevated on PMA-, LPS-, IL-17-, and TNF␣-stimulated HMVECs compared with unstimulated endothelial cells (Figure 2A ). In addition, treatment with LPS induced a 1.6-fold increase in the expression of ADAM-10 mRNA in HMVECs within 1 hour ( Figure  2B ). ADAM-10 expression on RA synovial fibroblasts was inducible by IL-1␤ ( Figure 2C ). The expression of ADAM-10 mRNA was also significantly elevated in IL-1␤-, IL-17-, PMA-, and LPS-stimulated RA synovial fibroblasts compared with unstimulated cells ( Figure 2D ).
ADAM-10-mediated release of potent angiogenic factors. In order to confirm the function of ADAM-10, we used siRNA directed against ADAM-10. The mean Ϯ SEM transfection efficiency in HMVECs was 88 Ϯ 2% (n ϭ 3 replicates), and the percent knockdown of ADAM-10 mRNA was 92 Ϯ 1% (n ϭ 3). The specific knockdown of ADAM-10 was confirmed by Western blotting, and ADAM-10 protein levels were shown to be decreased ( Figure 3A) . To examine whether knockdown was specific, we assayed for ADAM-8, ADAM-9, and ADAM-12 mRNA and observed 7 Ϯ 9% knockdown of ADAM-8 mRNA, 3 Ϯ 1% knockdown of ADAM-9 mRNA, and 0 Ϯ 0% knockdown of ADAM-12 mRNA (n ϭ 3). We then tested whether ADAM-10 cleaves potent angiogenic factors such as JAM-A, JAM-C, CXCL16, and CX3CL1 from the cell surface. When ADAM-10 was inhibited using siRNA, sJAM-A expression was decreased 17 Ϯ 2%, sJAM-C expression was decreased 78 Ϯ 19%, CXCL16 expression was decreased 71 Ϯ 1%, and CX3CL1 expression was decreased 65 Ϯ 9% (P Ͻ 0.05; n ϭ 4 replicates) (Figures 3B-E) .
Effect of ADAM-10 on angiogenesis. To determine the role of ADAM-10 in angiogenesis, we per- formed in vitro chemotaxis assays and Matrigel tube formation assays. Endothelial cell chemotaxis is an initial step in the angiogenic process. HMVECs were assayed for their chemotactic response to ADAM-10, using a modified Boyden chamber. In order to determine whether ADAM-10 mediates angiogenesis directly or indirectly, we performed HMVEC chemotaxis toward recombinant human ADAM-10, control siRNA-transfected HMVEC-conditioned medium, and ADAM-10 siRNA-transfected HMVEC-conditioned medium. HMVECs did not migrate toward recombinant human ADAM-10. In contrast, ADAM-10 siRNAtransfected HMVEC-conditioned medium caused a significant decrease in the chemotactic potential for HMVECs compared with control siRNA-transfected HMVEC-conditioned medium (mean Ϯ SEM number of HMVECs migrated 26 Ϯ 2 and 47 Ϯ 3, respectively; P Ͻ 0.05) ( Figure 4A ). ADAM-10 siRNA-treated HMVECs showed decreased migration toward RA synovial fluid compared with control siRNA (mean Ϯ SEM number of HMVECs migrated 19 Ϯ 2 and 35 Ϯ 4, respectively; P Ͻ 0.05) ( Figure 4B ).
To confirm which mediators are important in ADAM-10-induced angiogenesis, we used bFGF and VEGF as chemotactic stimuli. ADAM-10 siRNAtreated HMVECs showed decreased migration toward bFGF compared with control siRNA-treated HMVECs and untreated HMVECs (mean Ϯ SEM number of HMVECs migrated 3 Ϯ 0, 8 Ϯ 1, and 12 Ϯ 1, respectively; P Ͻ 0.05) ( Figure 4C ). ADAM-10 siRNA-treated HMVECs also had decreased migration toward VEGF compared with control siRNA-treated HMVECs and untreated HMVECs (mean Ϯ SEM number of HMVECs migrated 5 Ϯ 1, 10 Ϯ 1, and 12 Ϯ 2, respectively; P Ͻ 0.05) ( Figure 4D ), indicating that both bFGF and VEGF have important roles in ADAM-10-induced angiogenesis.
ADAM-10 siRNA-treated HMVECs showed de- (Figures 5A and B) . In addition, ADAM-10 siRNA-treated HMVECs showed decreased endothelial cell tube formation in Matrigel in response to VEGF compared with control siRNA-treated HMVECs and untreated HMVECs (mean Ϯ SEM number of endothelial cell tubes formed 4 Ϯ 1, 30 Ϯ 5, and 27 Ϯ 3, respectively; P Ͻ 0.05) (Figures 5C and D) . In order to examine the role of ADAM-10 in angiogenesis with respect to RA, we used untreated HMVECs, ADAM-10 siRNA-treated HMVECs, and control siRNA-treated HMVECs and cocultured these endothelial cells with RASFs in an in vitro chamber system. ADAM-10 siRNA-treated HMVECs from the coculture system showed decreased endothelial cell tube formation compared with control siRNA-treated and untreated HMVECs (mean Ϯ SEM number of endothelial cell tubes formed 4 Ϯ 2, 23 Ϯ 1, and 27 Ϯ 1, respectively; P Ͻ 0.05) (Figures 6A and B) .
We also examined the possibility that fibroblasts may affect HMVEC tube formation, potentially confounding our findings. To control for this possibility, we added HMVECs obtained from the coculture system directly to Matrigel containing RA synovial fibroblastconditioned medium and cultured them for 6 hours. ADAM-10 siRNA-treated HMVECs from RA synovial fibroblast-conditioned medium showed decreased endothelial cell tube formation compared with control siRNA-treated and untreated HMVECs (mean Ϯ SEM (Figures 6C and D) . These results showed that RA synovial fibroblasts were not involved in HMVEC tube formation, and that transfected HMVECs that were unable to express ADAM-10 had a reduced capacity to form tubes in vitro.
DISCUSSION
Angiogenesis is initiated by proangiogenic mediators that promote the release of proteolytic enzymes, including matrix metalloproteinases, resulting in the degradation of endothelial cell basement membrane and the perivascular extracellular matrix. In addition, specific angiogenic mediators activate endothelial cells and induce their proliferation and migration. The activated endothelial cells proliferate and migrate into the surrounding area, thus forming primary sprouts. Our group and others have previously shown that TNF␣ and other key mediators of RA pathogenesis, including fractalkine/ CX3CL1, CXCL16, JAM-A, and JAM-C, exist as cell surface-expressed and soluble proteins (22, 24, 29) . As soluble factors, these mediators promote inflammation and angiogenesis and thus drive the progression of RA.
ADAM-10 is a protease with a range of substrates that play roles in cancer proliferation, inflammation, and angiogenesis (30, 31) . These substrates include proinflammatory chemokines such as fractalkine/ CX3CL1 and CXCL16 (14, 15) . We previously demonstrated that several of these ADAM-10 substrates are up-regulated in RA ST or RA synovial fluid (24, 32) . However, the expression and regulation of ADAM-10 in RA have not been completely described. In the only previous study of ADAM-10 in RA, Komiya et al showed that ADAM-10 mRNA was found in RA ST at levels similar to those in OA ST, but information regarding localization of ADAM-10 expression in the different ST cell types was not provided (16) . Komiya and colleagues showed that the mRNA levels of other ADAMs, such as ADAM-8, ADAM-9, and ADAM-12, are similar between RA and OA. The present study clearly demonstrated that ADAM-10 is expressed on both endothelial cells and lining cells in normal, OA, and RA ST. In addition, the results showed that ADAM-10 was more highly expressed on endothelial cells and lining cells in RA ST than on endothelial cells and lining cells in OA and normal ST. We also observed that ADAM-8, ADAM-9, and ADAM-12 expression was not different between RA ST and OA ST.
Because of the more selective expression of ADAM-10 in RA ST than in OA ST, we focused on ADAM-10. In mice, ADAM-10 expression was significantly increased on the lining cells of arthritic joints compared with noninflamed control joints. In contrast, ADAM-10 expression on endothelial cells was low in the joints of both arthritic and nonarthritic mice. In addition, we observed that ADAM-10 expression was elevated in RA synovial fluid compared with PsA synovial fluid.
After observing ADAM-10 expression in RA ST endothelial cells and RA synovial fibroblasts, we determined which mediators control the expression of ADAM-10 in key cell types in RA ST. Western blotting and quantitative PCR revealed increased amounts of ADAM-10 expression on HMVECs and RA synovial fibroblasts upon stimulation with proinflammatory mediators such as TNF␣, IL-1␤, IL-17, PMA, or LPS. These data demonstrate the importance of both endothelial cell-and fibroblast-expressed ADAM-10 expression in RA.
We observed that ADAM-10 is also important in angiogenesis. Schulz et al showed that ADAM-10 actively plays a role in thrombin-induced decreases in endothelial cell-endothelial cell interactions (10) . Those investigators reported that knockdown of ADAM-10 in human umbilical vein endothelial cells (HUVECs) by siRNA impaired T cell transmigration. Glomski et al studied ADAM-10-deficient mice and showed that these mice had vascular abnormalities such as aberrant subcapsular hepatic veins, enlarged glomeruli, intestinal polyps containing endothelial cell masses, and abnormal endochondral ossification (31). Donners et al showed that VEGF induced ADAM-10-mediated cleavage of VE-cadherin, which increases endothelial cell migration (33) . They also demonstrated that VEGF increased vascular permeability in an ADAM-10-dependent manner, and that inhibition of ADAM-10 decreased endothelial cell migration.
After defining the activity of ADAM-10 using HMVEC chemotaxis and tube formation assays, we next assessed the role of ADAM-10 in angiogenesis with respect to RA. Specifically, we assessed the ability of ADAM-10 siRNA-transfected HMVECs cocultured with RA synovial fibroblasts to form tube structures. In general, coculture systems of normal dermal fibroblasts and HUVECs are used for tube formation assays (34) . However, the RA joint is rich in angiogenic mediators. A number of infiltrating cells contribute to the accumulation of angiogenic factors, including T cells and monocytes. In addition to these cells, resident ST lining fibroblasts account for many of the pathologic and clinical manifestations of RA (35) . Moreover, fibroblasts 106 ISOZAKI ET AL produce many inflammatory and angiogenic mediators, including cytokines and chemokines (36) . Therefore, we used RASFs to replicate the environment of the RA joint.
We observed that ADAM-10 siRNA-treated HMVECs had decreased endothelial cell tube formation activity compared with control siRNA-treated HMVECs in coculture with RA synovial fibroblasts or conditioned medium from the coculture system. ADAM-10 siRNA-treated HMVECs stimulated with bFGF or VEGF exhibited decreased migration compared with control siRNA-treated HMVECs stimulated with either bFGF or VEGF. We also controlled for the possibility that soluble factors such as bFGF or VEGF may be produced by RA synovial fibroblasts in the coculture system. This was done by isolating the treated HMVECs from the coculture system, washing them, and incubating these cells on Matrigel. We observed a decrease in tube-forming activity from the ADAM-10 siRNA-treated endothelial cells similar to that observed using the RA synovial fibroblastconditioned medium, confirming that the inhibitory effect on tube formation is endothelial cell specific.
RA synovial fibroblasts secrete angiogenic factors capable of inducing endothelial cell tube formation. However, the reduction in tube formation could be attributed to the lack of ADAM-10 expression in vitro. Because ADAM-10 cleaves potent angiogenic factors such as JAM-A, JAM-C, CXCL16, and CX3CL1 from the cell surface (25, (37) (38) (39) , limiting cleavage of these molecules via ADAM-10 inhibition may impair the ability of endothelial cells to initiate angiogenesis. We observed no HMVEC chemotaxis toward recombinant ADAM-10. However, we observed that ADAM-10 siRNA-transfected HMVEC-conditioned medium induced less HMVEC chemotaxis compared with control siRNA-transfected HMVEC-conditioned medium. This finding suggests that ADAM-10 mediates angiogenesis indirectly. In addition, decreased ADAM-10-mediated cleavage of adhesion molecules may result in increased endothelial cell-endothelial cell interactions mediated by JAMs, thus preventing migration of endothelial cells. It would be interesting to examine these mechanisms in an in vivo environment such as a murine model of collagen-induced arthritis. Indeed, the finding that ADAM-10 inhibits joint inflammation by reducing vasculature would be novel and exciting. The in vitro results presented here indicate that such a study would be relevant and would validate the use of ADAM-10-null mice to confirm our current findings.
We report here that ADAM-10 was overexpressed in RA ST. In addition, we demonstrated that endothelial cells and ST lining cells are a source of ADAM-10, and that proinflammatory mediators upregulate the expression of ADAM-10. Moreover, we showed that ADAM-10 plays a very important role in angiogenesis in RA.
